Search Within

MSK Grad Students

  1. "2013"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (21)
  3. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (26)
  2. Department of Medicine (26)
  3. GSK Faculty (26)
  4. Hematologic Malignancies, Division of (25)
  5. Sloan Kettering Institute Faculty (23)
  6. Bone Marrow Transplant (22)

More Groups

People
  1. Doris Ponce (19)
  2. Juliet Barker (17)
  3. Sergio Giralt (16)
  4. Andromachi Scaradavou (14)
  5. Sean Devlin (14)
  6. Nancy Kernan (13)

More People

Years
  1. 2013 (49)
Publications
  1. Blood (15)
  2. Biology of Blood and Marrow Transplantation (10)
  3. Nature (2)
  4. Advanced Materials (1)
  5. American Journal of Neuroradiology (1)
  6. Bioinformatics (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. Elsevier Inc. (10)
  3. Nature Publishing Group (4)
  4. Oxford University Press (3)
  5. American Association for Cancer Research (2)
  6. American Association for the Advancement of Science (2)

More Publishers

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses
    Meeting Abstract

    Huse, J. T.; Beal, K.; Zhang, J.; Kastenhuber, E. R.; Kaley, T. J.; Abrey, L. E.; Gutin, P. H.; Brennan, C. W.; Omuro, A. M. P.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Intensified mycophenolate mofetil (MMF) dosing every 8 hours is safe from the standpoint of engraftment and may ameliorate severe acute graft-versus-host disease (GVHD) after double-unit cord blood transplantation (CBT)
    Meeting Abstract

    Ponce, D. M.; Harnicar, S. J.; Devlin, S.; Hilden, P.; Evans, K. L.; Lubin, M. N.; Giralt, S. A.; Goldberg, J. D.; Perales, M. A.; Kernan, N. A.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Adverse cytogenetic abnormalities at diagnosis are the most important predictor of relapse post T cell depleted (TCD) allogeneic hematopoietic stem cell transplantation in patients with advanced myelodysplastic syndrome (MDS)
    Meeting Abstract

    Tamari, R.; Jakubowski, A. A.; Papadopoulos, E. B.; Giralt, S. A.; Goldberg, J. D.; Ponce, D. M.; Sauter, C. S.; Hilden, P.; Devlin, S.; Young, J. W.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Epigenetic profiling of leukemia stem cells in a model of TET2/FLT3-mutant AML
    Meeting Abstract

    Shih, A. H.; Jiang, Y.; Shank, K.; Pandey, S.; Viale, A.; Sun, Y.; Socci, N.; Robertson, A.; de Stanchina, E.; Hricik, T.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • The hematopoietic cell transplant-co-morbidity index (HCT-CI) predicts outcomes after T cell depleted (TCD) allogeneic HCT for AML and MDS
    Meeting Abstract

    Ratan, R.; Ceberio, I.; Hilden, P.; Devlin, S. M.; Malloy, M. A.; Barker, J. N.; Castro-Malaspina, H.; Jakubowski, A. A.; Koehne, G.; Papadopoulos, E. B.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • High day 28 ST2 biomarker levels predict severe day 100 acute graft-versus-host disease and day 180 transplant-related mortality after double-unit cord blood transplantation
    Meeting Abstract

    Ponce, D. M.; Hilden, P.; Mumaw, C.; Devlin, S.; Lubin, M. N.; Evans, K. L.; Prockop, S.; Scaradavou, A.; Kernan, N. A.; Giralt, S. A.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Analysis of 402 cord blood units to assess factors influencing infused viable CD34+ cell dose: The critical determinant of engraftment
    Meeting Abstract

    Purtill, D.; Smith, K. M.; Tonon, J.; Evans, K. L.; Lubin, M. N.; Byam, C.; Ponce, D. M.; Scaradavou, A.; Stevens, C. E.; Barker, J. N.
    Blood (2013)

    Fulltext@MSK | Save
  • Msi2 directly regulates the TGF-β signaling pathway and myeloid lineage bias in hematopoietic stem cells
    Meeting Abstract

    Park, S. M.; Deering, R. P.; Lu, Y.; Patrick, T.; Shenoy, V.; Lianoglou, S.; Al-Shahrour, F.; Leslie, C.; Ebert, B. L.; Lengner, C.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • A bi-specific T cell engaging monoclonal antibody (mAb) derived from a TCR-Like mAB specific for WT1/HLA-A0201 (ESK-BiTE) shows a potent activity against human AML and Ph+ ALL in mouse models
    Meeting Abstract

    Pankov, D.; Dao, T.; Wang, Y.; Scott, A.; Korontsvit, T.; Zakhaleva, V.; Veomett, N.; Curcio, M.; Doubrovina, E.; O'Reilly, R. J.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Two chemotherapy-based conditioning regimens compared to TBI-based conditioning secure consistent engraftment of T-cell depleted allogeneic HSCT, similarly low incidences of GVHD and favorable rates of disease-free survival (DFS)
    Meeting Abstract

    Koehne, G.; Boulad, F.; Klein, E. G.; Barker, J. N.; Castro-Malaspina, H. R.; Curran, K. J.; Giralt, S. A.; Goldberg, J. D.; Hasan, A. N.; Heller, G.; more...
    Blood (2013)

    Fulltext@MSK | Save